CarbaBac 1 gm/vial (IV Injection or Infusion)

1 gm vial: ৳ 1,200.00

Medicine Details

Category Details
Generic Meropenem trihydrate
Company Pharmasia limited
Also available as
Carbabac 500 mg injection

Indications

  • Pneumonia and Nosocomial Pneumonia
  • Urinary Tract Infections
  • Intra-abdominal Infections
  • Gynaecological Infections
  • Skin and Skin Structure Infections
  • Meningitis
  • Septicaemia
  • Pulmonary infections in cystic fibrosis
  • Empiric treatment for presumed infections in patients with febrile neutropenia

Pharmacology

Meropenem is a carbapenem antibiotic for parenteral use that interferes with bacterial cell wall synthesis, showing potent bactericidal activity against a broad spectrum of bacteria.

Dosage

  • Adults:
    • 500 mg to 1 gm intravenously every 8 hours
    • 1 g intravenously every 8 hours for certain infections
    • Up to 2 gm intravenously every 8 hours for cystic fibrosis
  • Children:
    • 10 to 40 mg/kg intravenously every 8 hours
    • 20 mg/kg intravenously every 8 hours for intra-abdominal infections
    • 25-40 mg/kg intravenously every 8 hours for cystic fibrosis
    • 40 mg/kg intravenously every 8 hours for meningitis

Administration

Meropenem should be administered by intravenous infusion over approximately 15-30 minutes or as intravenous bolus over approximately 3-5 minutes.

Interaction

Probenecid competes with CarbaBac for active tubular secretion and thus inhibits the renal excretion, potentially increasing plasma concentration. CarbaBac may reduce serum valproic acid levels.

Contraindications

Meropenem is contraindicated in patients with demonstrated hypersensitivity to the product.

Side Effects

  • Inflammation
  • Thrombophlebitis
  • Pain at the site of injection
  • Skin reactions like rash, pruritus, urticaria
  • Abdominal pain
  • Nausea
  • Vomiting
  • Diarrhea
  • Headache

Pregnancy & Lactation

Pregnancy Category B. Caution should be exercised when Meropenem is administered to a nursing woman.

Precautions & Warnings

  • Discontinue if allergic reaction occurs
  • Use in hepatic disease patients with careful monitoring of transaminase and bilirubin levels

Use in Special Populations

  • Dosage adjustment for renal impairment
  • No dosage adjustments for hepatic impairment
  • Hemodialysis patients should receive CarbaBac after dialysis
  • No dosage adjustments necessary in elderly unless creatinine clearance is <51 ml/min
  • Efficacy and tolerability in infants under 3 months not established

Overdose Effects

Treatment should be symptomatic. Haemodialysis will remove CarbaBac and its metabolite in subjects with renal impairment.

Therapeutic Class

Other beta-lactam Antibiotics

Reconstitution

CarbaBac is compatible with various infusion fluids and maintains potency for up to 3 hours at up to 25°C or 13 hours at up to 5°C.

Storage Conditions

Vial should be stored in a cool, dry place (below 30°C), away from light and moisture.

Related Brands